Roquinimex, Linomide, a quinoline derivative with pleiotropic immunomodulatory activity, has previously been shown to enhance natural killer (NK) cell number and activity after ABMT in patients with AML. In this study 278 AML patients in remission were randomized to receive Roquinimex 0.2 mg/kg body weight or placebo twice weekly for 2 years following ABMT. Out of 139 patients in each group, 109 Roquinimex patients and 108 placebo patients were in their first CR. Median age at inclusion was 41 years for Roquinimex patients and 39 years for placebo patients. Twelve patients in each group had their marrow purged prior to reinfusion. Relapse and death were study endpoints. Surviving patients were followed for 2.6 to 6.9 years. The total number of relapses was 60 in the Roquinimex group and 63 in the placebo group (not significant). Leukemiafree and overall survivals were similar in the two groups. Recovery of platelet counts was significantly delayed in the Roquinimex group as compared to placebo. No other significant differences regarding toxicity parameters were recorded. In conclusion, previous findings on NK cells could not be confirmed and the study showed no benefit for Roquinimex over placebo regarding relapse or survival following ABMT for AML in remission. Bone Marrow Transplantation (2000) 25, 1121-1127. Keywords: Roquinimex; Linomide; ABMT; AML The overall annual incidence of AML is about three per 100 000 population with an increased incidence with ageing. Median age is 62-65 years. Intensive combination chemotherapy may induce complete remission (CR) in 60-80% of patients less than 60 years of age.
ABMT. [3] [4] [5] [6] [7] DFS is less for patients transplanted at later stages of AML.
A role for immunologic mechanisms for eradication of residual leukemia cells after allogeneic bone marrow transplantation has been defined as the GVL phenomenon. [8] [9] [10] GVL is mediated via T lymphocytes, NK cells or other mediators as well. [11] [12] [13] [14] [15] [16] T lymphocytes with a reactivity against leukemic cells distinct from the reactivity against normal marrow cells have been isolated. 13, 17 NK cells as well as lymphokine-activated killer (LAK) cells have demonstrated lysis of allogeneic as well as autologous leukemia blast cells. [18] [19] [20] Furthermore, NK cell activity in AML in CR has been shown to be inversely correlated with the risk of relapse. 21 NK activity and LAK cell inducibility are more prominent in complete remission than in frank AML. [22] [23] [24] These results, together with the observation that tumor cells might inhibit LAK generation, 20, 25 made it conceivable that the best prospects for enhancement of NK cell activity were in a state of minimal residual disease.
Activated macrophages, like NK and LAK cells, can be non-specifically cytotoxic to tumor cells independent of the MHC. [26] [27] [28] [29] [30] However, the role of monocytes/macrophages, if any, in the eradication of residual AML cells in remission remains to be determined. Roquinimex (Linomide) has shown broad immunomodulatory properties in preclinical studies. NK cell number and activity were enhanced in mice during the recovery phase after myeloablative therapy. 31, 32 Antigen-induced T cell responses have been modulated in various models. 33, 34 Macrophage cytotoxicity has been enhanced in tumor-bearing rats. 35 Immunomodulatory properties of Linomide in clinical studies have been shown in patients with autoimmmune diseases, 36 various cancers, 37 and healthy volunteers (Linde A, unpublished). Linomide given intermittent courses to patients with AML in remission after autotransplantation, increased the number and activity of NK cells as well as the number of monocytes. 39, 40 The toxicity of Linomide has in general been manageable with symptomatic treatment. Side-effects have mainly consisted of musculoskeletal aches, nausea, vomiting, edema, skin rash, diarrhea and fatigue. [36] [37] [38] [39] [40] In ongoing clinical studies a 2% incidence of pericarditis and pleuritis as well as a 0.5% incidence of acute myocardial infarction has been reported.
With AML perceived as a disorder sensitive to manipulations of immune function and Roquinimex being an agent with broad immunomodulatory activity and manageable toxicity, it was decided to investigate whether Linomide could prolong the time to relapse or reduce the relapse rate in patients with AML in remission after ABMT.
Patients, materials and methods
Patients with cytochemically verified primary AML in first or later CR, and for whom an ABMT was planned, were eligible for entry into the trial. Morphologic classification and CR definition followed the French-American-British system. The study was carried out at 39 centers in 10 European countries, and was approved by the national health authorities and the local ethics committees.
Linomide
During screening for anti-inflammatory agents, Roquinimex (Linomide; Pharmacia & Upjohn, Stockholm, Sweden) was discovered to have potent immune stimulatory properties. Its chemical name is N-phenyl-N-methyl-1,2-dehydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbo-xamide. Its molecular formula is C 18 H 16 O 3 N and its molecular weight is 308.33.
Randomization
Randomization was made after the patient's informed consent was obtained and before starting the myeloablative treatment. The patients were stratified by center and by first or later CR. Neither the patients nor the investigators nor the sponsor's study management personnel had access to information on treatment assignments.
Treatment schedule
Linomide or placebo treatment was initiated on day 14 (12) (13) (14) (15) (16) after ABMT and the drug was administered twice weekly. The dose was 0.05 mg/kg body weight (2.5-5 mg) twice during the first week and 0.10 mg/kg (5-10 mg) twice during the second week. From the third week on, the dose was 0.20 mg/kg (10-20 mg) twice weekly for 2 years. The dose was adjusted downwards to the tablet sizes available (2.5, 5 and 10 mg). Dose modifications were made in case of suspected toxic side-effects. If chemotherapy for relapse had to be instituted, the treatment with study medication was discontinued. Concomitant use of chemotherapy or other immunomodulating drugs was not allowed.
Assessments
Relapse was defined as Ͼ10% blast cells in a normocellular bone marrow aspirate, or as extramedullary leukemia. If the marrow blast percentage was 11-20, a second aspirate had to be evaluated within 2 weeks; the first one was recorded as date of relapse. If the blast percentage was above 20, a second aspirate was not needed. After discontinuation of study treatment due to relapse or for any other reason, the patients were followed for survival.
Time to relapse as well as survival were defined as the time from ABMT to relapse or death. Relapse rate was calculated as the percentage of patients with relapse after 1 and 2 years. Complete blood counts were obtained at each visit, and bone marrow was aspirated every 3 months and as clinically indicated.
The effect of Linomide on immunological reconstitution in a subgroup of 97 patients was studied by means of flow cytometry. Samples of heparinized blood were drawn 48 h after the latest dose of study medication, and mononuclear cells were Ficoll separated. Cell numbers were assessed by FACS, and the following cells were enumerated: NK-like cells (Leu 11-FITC (CD16), Leu 19-PE (CD56) together with Leu 4-FITC (CD3)), T cells (Leu 4-FITC (CD3)), B cells (Leu 12-FITC (CD19)) and monocytes (Leu M3-PE (CD14)).
For lymphoid cells CD45 (FITC) always had to be Ͼ90% and Leu M3 (CD14-PE) Ͻ5% in the gate. The proportion of CD14 ϩ cells was expressed as percent of all mononuclear cells, not of gated lymphocytes. Results were obtained from the Leucogate staining.
In order to permit comparisons between patients at various centers, consistency of FACS analysis performance between centers was confirmed.
Autoantibodies were analyzed at admission, month 6 and month 24 in order to detect possible immunologic complications of the treatment.
Statistical methods
Demographic variables were assessed using descriptive statistics. The two treatment groups were compared using the normal approximation of the Wilcoxon rank sum test when the variables were continuous and the Pearson's chisquare test, without continuity correction when the variables were presented in contingency tables. When the events in the row x column table cells were few, a generalization of the Fisher's exact test was used.
The following variables were used as prognostic factors in the analysis of survival, time to relapse and leukemiafree survival: age, number of complete remissions (CR = 1 and CR Ͼ 1), FAB classification, extramedullary involvement and country. Data from diagnosis of AML were incomplete (eg cytogenetics) and could not be evaluated.
Relapse rate at 1 year included all patients who relapsed within 1 year of observation. Time to relapse, survival and leukemia-free survival (LFS) used all available information about the patients (intent to treat analysis). Patients not showing relapse or death were censored at the date of latest follow-up visit.
The number of patients required for the efficacy analysis was based on time to relapse and proportion of relapses at 12 months. With a significance level of 5%, a one-tailed test, a power of 80% and an expected median time to relapse of 12 months for placebo and 18 months for Linomide 2 ϫ 109 = 218 patients were needed. With this number of patients it was considered possible to detect a true difference between a placebo relapse proportion of 50% and a Linomide relapse proportion of 33% at 12 months.
All models above were analyzed using the Cox regression model (SAS PHREG). The results from the chosen models included an estimate of the hazard ratio with a 95% confidence interval.
Ethics
The Study Protocol was reviewed for scientific and ethical validity and approved by the Ethics Committees or Institutional Review Boards of each of the 39 study centers as well as by the Health Authorities of the 10 participating European countries.
Prior to enrollment, each patient was informed, verbally and in writing, about the objectives and procedures of the study, the possible risks involved and the computer processing of individual patient data.
Informed consent was obtained from the patient either in writing or orally according to local regulations.
Results

Patients
Between February 1991 and May 1994, 278 patients were randomized. Only 277 patients underwent ABMT as patient No. 121 (Linomide) relapsed prior to ABMT. Reasons why 11 patients never received study medication were: death (1), refusal (2), protocol violation (1), other reason (1) in the Linomide group and death (2), adverse event (1), other reason (3) in the placebo group. Thus 266 patients received at least one dose of study medication after ABMT; 133 Linomide and 133 placebo.
Patient characteristics are given in Table 1 . There were significantly more males in the Linomide group compared to placebo (P = 0.012). Sex was not of prognostic significance regarding the study endpoints. Time from diagnosis to ABMT and time from attainment of CR to ABMT did not differ between the arms (data not shown). Thus, the two treatment arms were well balanced. The impact of the cytogenetic risk profiles could not be studied since too few samples were analyzed for cytogenetics. Table 2 shows ABMT data. One patient randomized to Linomide treatment did not undergo ABMT. Twelve patients in each treatment group had the marrow purged before reinfusion. Busulphan plus cyclophosphamide was the most commonly used conditioning regimen. There were no differences between the two treatment groups regarding the ABMT procedure.
Of 133 patients treated with Linomide, six died and 34 relapsed while on medication.
Fifty-seven patients were withdrawn for the following reasons: refusal (10), adverse event (38), protocol violation (2), other reason (6), unassociated disease (1). Thus, 36 Linomide patients completed 2 years treatment according to the protocol.
Of 133 placebo patients, one died and 47 relapsed while on medication. Thirty-four patients were withdrawn for the following reasons: refusal (7), adverse event (24), other reason (3), unassociated disease (1). Thus, 51 placebo patients completed 2 years treatment according to the protocol.
Efficacy
The number of patients with relapse and the relapse rates are shown in Table 3 . There was no statistically significant difference between the treatment groups. Figure 1 shows overall freedom from relapse. Thirteen late relapses (Ͼ12 months post ABMT) occurred in the Linomide group as compared with 17 late relapses in the placebo group.
Median observation time of surviving patients was 1629 days for placebo and 1586 days for Linomide-treated patients. The observation period was from February 1991 to November 1998. Survival data were analyzed using Kaplan-Meier plots and Cox regression. There were no statistically significant Table 3 Number and rates of relapses by treatment group Relapse rate: all patients, and at 1 and 2 years post ABMT, respectively. Distribution by treatment group. All randomized patients, n = 278. differences between the treatment groups regarding leukemia-free or overall survival (Figures 2 and 3 ). There were no statistically significant differences between Linomide and placebo within any country or complete remission group (CR1 vs CR Ͼ1) regarding freedom from relapse or leukemia-free survival (data not shown).
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Median time to relapse has not yet been reached for any of the populations. Median estimated overall survival is 1126 days for Linomide and 1102 days for placebo-treated patients. Estimates on leukemia-free survival are 505 days for Linomide and 520 days for placebo.
The maximum absolute number of circulating immune cells has been calculated as the maximum value after treatment initiation by use of the Wilcoxon test. In Table 4 . the maximum absolute value is described. There were significantly lower numbers in the Linomide group than in the placebo group regarding CD19 (B cells) (P = 0.0022) and CD56 (NK cells) (P = 0.0404), and a borderline significance regarding CD16 (NK cells) (P = 0.0504). In the visit 
CD3
Ϫ , P = 0.04; CD16 ϩ , P = 0.05). In the visit by visit analysis, there were no differences between the two treatment groups regarding B cells, NK cells, or monocytes.
by visit analysis, there were no differences between the two treatment groups regarding B cells, NK cells, or monocytes.
Safety
Two years of treatment according to the protocol was completed by 87 patients (51 placebo, 36 Linomide). The median amount of drug administered to the patients was for Linomide 485 mg (range 2.5-3105 mg), and for placebo the corresponding value was 1150 mg (range 2.5-4715 mg).
Clinical adverse events were similar between the two treatment groups, both as specific types of events and as events grouped by body system. All treated patients had recordings of adverse events (Table 5) . Twenty-nine patients (12 placebo, 17 Linomide) died without a recording of relapse. Death was associated with infection or bleeding or leuko-or thrombocytopenia in nine placebo patients who There were no statistically significant differences between the two treatment groups regarding clinical adverse events. Most common events; from checklist. Reasons for withdrawal from study treatment are shown in Table 6 . Twenty-four placebo and 38 Linomide patients were withdrawn due to adverse events, and seven placebo and 12 Linomide patients because of refusal. Of the 24 placebo patients withdrawn due to adverse events, eight (33%) were alive and in continuing complete remission at the end of the follow-up period, whereas 21 of 38 (55%) Linomide patients withdrawn due to adverse events were alive and relapse-free at the end of the observation period.
Thirty patients in the placebo group and 41 patients in the Linomide treatment group had recordings of serious adverse events. Twelve patients in the placebo group had 18 serious adverse events and 20 patients in the Linomide group had 21 serious adverse events that were assessed as possibly or probably related to administration of study medication. Of such events, 13 in the placebo group and 14 in the Linomide group were cytopenia, infection, or bleeding.
Pericarditis occurred in four patients in the Linomide group, two reported as serious. One of these patients developed pericarditis before start of study medication. One Linomide treated patient had a myocardial infarction.
The frequency of edema did not differ significantly between the groups. However, there were more patients with severe edema in the Linomide as compared to the placebo group. A similar finding was made for musculoskeletal discomfort. Moderate vomiting as well as moderate nausea/vomiting was reported somewhat more frequently for Linomide than for placebo patients, but there were no statistically significant differences. Peripheral neuropathy Table 6 Reasons for termination of study treatment (No. of patients) Bone Marrow Transplantation of various categories seemed to occur somewhat more frequently in the Linomide group, but there were no statistically significant differences. Recovery of platelet number was significantly delayed in the Linomide treatment group as compared to placebo (Figure 4) . However, there were no statistically significant differences between the two treatment groups regarding treatment-related mortality, serious adverse events or hemorrhagic complications. Recovery of neutrophils seemed to be delayed for Linomide-treated patients, although this was not statistically significant. Recovery of red cells and hemoglobin was similar between the two treatment groups.
Reason
Placebo Linomide Total
There were no significant differences between Linomide and placebo-treated patients respectively, regarding liver function tests, creatinine, ESR, CRP, U-protein or Uglucose. No autoantibodies developed in either of the two patient groups.
Discussion
The main finding in the final analysis of the present study was the lack of statistically significant differences between Linomide and placebo regarding the study endpoints: time to relapse, relapse rate, leukemia-free survival and overall survival. However, there were fewer late relapses in the Linomide group than among placebo-treated patients, indicating the possibility of an antileukemic effect of Linomide in patients with very few residual AML cells after ABMT. Therefore, a continued follow-up of the patients for relapse and survival has been performed till the end of 1998. At this time, the data are considered sufficiently mature for a final conclusion to be reached.
Preclinical studies as well as early clinical pilot studies showed that Linomide enhanced the number of NK cells in a regenerating bone marrow. 31, 32, 39, 40 Those findings could not be confirmed in the present large randomized study. Instead, maximum B cell and NK cell numbers seemed to be decreased by Linomide. A similar decrease Bone Marrow Transplantation is also reported in a small subgroup analysis. 38 Reasons for this discrepancy might be the divergence between species and the small number of patients in the early clinical studies. Treatments in previous studies were of short duration, and a different effect of Linomide with a longer treatment duration cannot be excluded. It is also possible that different results could be obtained with another dose or dose schedule, eg intermittent administration.
Delayed regeneration of platelets after the ABMT was the only statistically significant finding in the safety evaluation of Linomide. However, this finding was not translated into a higher number of serious or fatal bleedings among Linomide-treated patients. Clinical adverse events were not different between the treatment groups. Previous clinical studies had shown that administration of Linomide had been associated with, eg musculoskeletal discomfort, edema, skin rashes, headache, as well as other side-effects. The lack of significant differences between the groups could have been due to disturbing side-effects associated with the ABMT as such, and possibly also to the low number of patients (87 out of 278) who actually completed the 2 year treatment according to the protocol.
Studies of interleukin-2 in AML in minimal residual disease have shown encouraging as well as disappointing results in phase II studies, 41, 42 and randomized studies have not shown benefits of IL-2 in AML. One theoretically possible reason for the apparent lack of benefit from Linomide or IL-2 in AML could be reactive oxygen metabolites, generated by monocytes activated concomitantly with NK cells and T cells during treatment with IL-2 or Linomide. Such reactive oxygen metabolites have been shown to inhibit activation of NK cells and T cells. 43, 44 The finding of a lower number of NK cells in the treatment group than in the control group was in contrast to earlier findings of increased NK cell numbers upon treatment with Roquinimex. 31, 32, 39, 40 Since Roquinimex has been shown to activate monocytes/macrophages, it can be hypothesized that reactive oxygen metabolites from such cells could have initiated apoptosis in NK cells, as has been shown experimentally. 45 In conclusion, Roquinimex did not show superiority as compared to placebo regarding time to relapse, relapse rate, leukemia-free survival or overall survival.
